Tom3 schreef op 18 januari 2022 18:05:
Arrowhead is een screaming buy volgens The Motley Fool:
Arrowhead Pharmaceuticals: A plethora of major catalysts
Arrowhead is a developmental-stage biotech specializing in RNA interference (RNAi) drugs. Apart from its novel drug development platform, the company is unique in terms of its value proposition to potential investors for a couple of reasons.
To start with, it isn't focused on one or two core drugs, like many other clinical-stage biopharmas. Instead, Arrowhead has a whopping 10 drug candidates under development at the moment, and several more on the way soon, for a wide variety of high-value indications. The biotech is able to pursue numerous pipeline candidates simultaneously due to its ability to attract deep-pocketed big-pharma partners. At last count, Arrowhead had major partnership agreements in place with Amgen, GlaxoSmithKline, Horizon Therapeutics, Johnson & Johnson (NYSE:JNJ), and Takeda Pharmaceutical. J&J is even a major shareholder.
Why is Arrowhead's stock a screaming buy right now? The biotech is slated to report top-line results from several important clinical programs this year. Chief among these updates, Arrowhead and J&J are scheduled to provide multiple clinical updates over the course of 2022 for their joint hepatitis B RNAi therapeutic known as JNJ-3989; mid-stage trial results are expected by mid-2022 for the Takeda-licensed liver disease drug TAK-999; and mid-stage trial results are also due out by the middle of the year for the Amgen-partnered ApoA RNAi therapeutic dubbed AMG-890. A hit on any or all of these clinical updates ought to light a fire undernearth Arrowhead's shares.